Recon: Illumina closes Grail acquisition without go ahead from regulators; FDA approves Lilly, BI drug for heart failure
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy